DelfaGLP-1 Atlas

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

12 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

12

Trials led

1

Active

2,054

Total enrollment

8

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 1
7
Phase 2
2
Phase 3
3

Trials by status

Not yet recruiting
1
Completed
7
Unknown
4

Trials led

Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminBMI 20-40Ph 3Unknown587
A Phase 3 Study of HS-20094 in Patients With T2DMBMI ≥23Ph 3Not yet recruiting546
Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 PatientsBMI 20-40Ph 3Unknown406
A Study of HS-20094 in Patients With T2DMBMI ≥22Ph 2Completed275
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese VolunteersBMI 19-24Ph 1Completed62
A Study of HS-20094 in T2DM ParticipantsHbA1c 7.5-10%Ph 2Completed54
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese VolunteersBMI 19-28Ph 1Completed40
Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal FunctionBMI ≤28Ph 1Unknown24
Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult SubjectsBMI 18-25Ph 1Completed16
Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult SubjectsBMI 18-25Ph 1Completed16
Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult SubjectsBMI 18-25Ph 1Completed16
Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic PatientsBMI 18.5-30Ph 1Unknown12